A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer

作者：Qvortrup C^*; Jensen B V; Fokstuen T; Nielsen S E; Keldsen N; Glimelius B; Bjerregaard B; Mejer J; Larsen F O; Pfeiffer P

来源：Annals of Oncology, 2010, 21(1): 87-91.

DOI：10.1093/annonc/mdp272

• capecitabine
• chronotherapy
• colorectal cancer
• oxaliplatin
• randomized
• short-time infusion

Patients and methods: One hundred and forty-one patients with unresectable mCRC were enrolled in a randomized study comparing standard XELOX (XELOX30), arm A, and XELOX30Chron, arm B-both with short-time infusion of oxaliplatin-with the primary aim of reducing overall toxicity.
Results: Overall toxicity grade 2-4 was 90% versus 85%, P = 0.47 and grade 3-4 was 31% versus 37%, P = 0.6 in arm A and B, respectively. We found no significant differences in median overall survival (17.6 versus 15.5 months; P = 0.068) and median progression-free survival (8.9 versus 8.8 months; P = 0.7). The incidence of grade 3 neuropathy was 16% in arm A and 19% in arm B (P = 0.7) after a cumulative dose of oxaliplatin of 1000 mg/m(2).
Conclusion: XELOX30Chron does not reduce toxicity or improve efficacy. A 30-min infusion of oxaliplatin is safe and does not increase the severity of chronic neuropathy.

• 出版日期2010-1